We are delighted to announce the appointment of our new Chairman of the Board, Nachum (Homi) Shamir. Homi has significant top management and board experience, most recently as the longtime CEO and Chairman of the Board of Luminex Corporation, where he among other things led the successful acquisition of Nanosphere and the sale of the group to Diasorin. In addition to his significant general management experience, Homi brings deep experience within clinical diagnostics and medical devices. Homi has served on several boards over the years, including Given Imaging (acquired by Covidien), Cogentix Medical (acquired by Laborie Medical Technologies) and Invedo Medical (acquired by Ambu).

Ingo Chakravarty has also joined the Board of Directors of SSI Diagnostica Group. Ingo most recently served as President and CEO of Mesa Biotech which he successfully developed and grew until its sale to Thermo Fisher Scientific. Prior to this, Ingo has spent most of his career in infectious disease diagnostics at Roche, Hologic and GenMark. Separate to his Board role at SSI Diagnostica Group, Ingo is currently an operating partner at Northpond Ventures.

Following the acquisition of Techlab last year, SSI Diagnostica Group is now launching its new 5 year strategy. The aim is to further accelerate growth as one global organization serving the vaccine and IVD infectious disease markets. The strategy builds on the group’s strong position within gastric, respiratory and blood borne diseases, where the Group supports its customers in preventing disease outbreaks, disease surveillance and patient diagnostics.

Our new board members will contribute to the success of our strategy, and I very much look forward to the collaboration, says Christina Lindved, CEO of SSI Diagnostica Group.

In addition to Homi and Ingo, Stig Lokke Pedersen and Patrik Dahlen will continue to serve on the Board of Directors of the Group.

Rasmus Molander
Board member, SSI Diagnostica Group
Co-Managing Partner, Adelis Equity Partners